- Home
- IVT vs RCUS Comparison
IVT vs RCUS Comparison
Compare IVT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVT | RCUS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.9B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IVT | RCUS |
|---|---|---|
| Price | $33.18 | $25.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $32.50 | $31.90 |
| AVG Volume (30 Days) | 422.3K | ★ 788.7K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 647.37 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $299,169,000.00 | $247,000,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $5.25 | $45.62 |
| P/E Ratio | $475.07 | ★ N/A |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $26.52 | $7.92 |
| 52 Week High | $33.40 | $28.72 |
Technical Indicators
Market Signals| Indicator | IVT | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 57.35 |
| Support Level | $30.42 | $23.91 |
| Resistance Level | N/A | $26.70 |
| Average True Range (ATR) | 0.62 | 1.10 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 85.52 | 84.53 |
Price Performance
Historical ComparisonAbout IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.